We started our work in the middle of the Polish academic life. The main inspirer of the PMC creation was prof. Anna Dmoszyńska,
from whom we received congratulations and strong support. Professor Andrzej Jakubowiak from the University of Chicago, which is committed to supporting Polish scientific aspirations, also played a very important role. The lack of organization, which is the PMC, was one of the main reasons for the failure of the study proposed by him in 2010. Despite the enthusiasm of the Polish researchers and sponsors of the project, there was no formal feasibility to perform such an inter-institutional trial. Prof. Roman Hájek from the Department of Pathology at the Medical Faculty of Masaryk University in Brno and prof. Xavier Leleu Service des Maladies of du Sang, Hopital Huriez in Lille, France, gave impetus to the idea of founding a direct group during the PTHiT Congress in Poznan. Many people in Poland, who keep in mind the research on multiple myeloma, support us.
We want to cooperate with groups similar to ours, such as PALG or PLRG. We want to benefit from their experience and exchange research ideas. We also cooperate with the Polish Myeloma Group (PGSz), which is an essential and permanent part of Polish hematology. Without the support of the Polish hematologists associated in PGSz our association will not succeed. We want to and we need to cooperate with PGSz. We would like to implement ideas that will be raised by the PGSz. We somehow want to
be the "executive body" of the Polish Myeloma Group.
A clinical trial is the most advanced form of scientific research based on trust in the patient-doctor /researcher relationship. Without it, there is no progress in medicine. The law imposing the burden of treatment on the researcher virtually prevents the organization of clinical trials in Poland- denying the patient the opportunity to use the newest drugs. We want to change that, among other things, by the spread of investigator-initiated research, which is practically absent in Poland unlike in Western Europe and the USA. If they can do it, so can we. There is a difficult path ahead of us, but the first step is always the hardest. We believe that the success will come sooner or later.
We invite you to cooperate with us.
President of the board of the Polish Myeloma Consortium